New blood test could spot cancer cells better in advanced breast and prostate cancer

NCT ID NCT06904625

Recruiting now Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatment. The goal is to find a more sensitive method to track cancer spread, which could help guide future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Blood sample collection for circulating tumor cell detection using CellSearch, Parsortix, and SmartCatch technologies
What this could lead to: If successful, this study could identify a more sensitive blood test for detecting cancer cells, potentially improving monitoring of metastatic breast and prostate cancer.
What could go wrong: This is a small, early pilot study (54 patients) that only compares detection methods, not treatment outcomes. The new techniques may not prove more effective than the standard approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm metastatic prostate carcinoma Neoplastic Cells, Circulating prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

IUCT-O
RECRUITING

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.